Rajiv Patni
CIK 1616200 · EVP, Chief R&D Officer · last filed 2026-01-12
Rajiv Patni is an EVP, Chief R&D Officer who has filed 19 SEC Form 4 insider transactions across 5 companies since 2015. The most recent filing, for BTAI, was dated Jan 12, 2026. Across all open-market trades the lifetime net is −$64.0K, making them a net seller over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$0
5
19
-$64.0K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| BTAI | Director | — | $1.14 | — | $0 | 2 | 2026-01-12 |
| QNCX | Director | — | $0.93 | — | $0 | 3 | 2025-06-06 |
| REATA PHARMACEUTICALS INC (RETA) Delisted | EVP, Chief R&D Officer | 0 | $172.36 | $0 | $0 | 2 | 2023-09-26 |
| PORTOLA PHARMACEUTICALS INC (PTLA) Delisted | EVP, CMO | 35,000 | — | — | $0 | 2 | 2020-07-02 |
| Adamas Pharmaceuticals Inc (ADMS) Delisted | Chief Medical Officer | 49,141 | $8.22 | $403.9K | -$64.0K | 8 | 2019-04-10 |
Recent Filings
19 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-01-12 | BTAI | Grant (A) | — | $0 | EDGAR |
| 2025-06-06 | QNCX | Grant (A) | — | $0 | EDGAR |
| 2025-01-16 | BTAI | Grant (A) | — | $0 | EDGAR |
| 2024-06-07 | QNCX | Grant (A) | — | $0 | EDGAR |
| 2024-02-15 | QNCX | Grant (A) | — | $0 | EDGAR |
| 2023-09-26 | REATA PHARMACEUTICALS INC (RETA) Delisted | Disp (D) | −45,000 | $0 | EDGAR |
| 2023-06-14 | REATA PHARMACEUTICALS INC (RETA) Delisted | Grant (A) | +45,000 | $0 | EDGAR |
| 2020-07-02 | PORTOLA PHARMACEUTICALS INC (PTLA) Delisted | Disp (D) | — | $0 | EDGAR |
| 2020-03-03 | PORTOLA PHARMACEUTICALS INC (PTLA) Delisted | Grant (A) | +35,000 | $0 | EDGAR |
| 2019-04-10 | Adamas Pharmaceuticals Inc (ADMS) Delisted | Grant (A) | +30,000 | $0 | EDGAR |